Tissue Regenix Group PLC Research Update

Tissue Regenix Group PLC announced that a pre-clinical study, undertaken by Professor Alan Dardik from the Department of Surgery at Yale University, using Tissue Regenix Group plc's ('Tissue Regenix' or 'the Company') patented dCELL technology, has been published in a peer-reviewed paper and has demonstrated that the Tissue Regenix dCELL matrix can deliver enhanced cell re-population compared to Vascu-Guard (Synovis, US) - a bovine derived matrix. dCELL is a process which removes cells and other components from human and animal tissue allowing it to be used without anti-rejection drugs to replace worn out or diseased body parts. The pre-clinical study examined the types of cells that repopulated Tissue Regenix's dCELL scaffold and compared these to Vascu-Guard, once both had been implanted. The study was performed using the Company's vascular patch that is currently approved for use in the EU. Findings highlighted that Tissue Regenix' dCELL Vascular Patch was effective at attracting the right stem cell types quickly for the function they will have in the final tissue structure. This, in conjunction with the Company's own clinical observations, gives further support to the expectation that patients can get the benefit of stem cell repopulation without the significant issues and costs associated with using externally sourced stem cells.